Use of fluoroquinolones in cats

Cannon, Martha; Gould, David; Caney, Sarah; Foster, Darren; Harvey, Andrea; Reed, Nicki; Sparkes, Andrew H; Tasker, Séverine; Stadt-Gould, Maud Van de

doi:10.1136/vr.160.1.32

Cited by 3 publications

(2 citation statements)

References 4 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To obtain more regular PK profiles of enrofloxacin in cats the drug should be administered orally on an empty stomach as food is known to affect the absorption of fluoroquinolones [ 4 , 26 ]. However, the temperament of the cat makes this task difficult, and resort to IM or SC administration of enrofloxacin entails many side effects both in the injection site, and potentially making retinal toxicity more likely to occur [ 6 , 23 , 24 ] Hence, despite the approval in many parts of the world of parenteral administration of enrofloxacin, this route should be reserved for those cases in which bacterial susceptibility has been demonstrated [ 10 , 21 , 27 ].…”

Section: Discussionmentioning

confidence: 99%

“…Although enrofloxacin has been on the market for cats for more than three decades and is recommended for various bacterial infections in this species [ 1 , 2 , 3 , 4 ], a proper pharmaceutical preparation suitable for them, has not been developed. It is currently approved in the United States by the Food and Drug Administration, as well as in many countries for use in cats.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of a Tasteless Enrofloxacin Pharmaceutical Preparation for Cats. Naive Pooled-Sample Approach to Study Its Pharmacokinetics

Gutiérrez

Tapia

Gutiérrez

et al. 2021

Animals

View full text Add to dashboard Cite

Available pharmaceutical preparations of enrofloxacin injected SC or IM to cats are likely to cause adverse tissue reactions in the injection sites (pH of the drug preparations is ≥10.4). Tablets often induce abundant ptyalism and vomiting, casting doubt on the efficacy of the drug administration maneuver. In addition, the reported oral bioavailability is very low. In this trial, the oral pharmacokinetics of dried alginate beads of enrofloxacin (DABE) administered by concealing them in the cat’s moist food or morsels, is described. A naïve polled sampling approach was chosen with fourteen adult healthy cats. Neither their housing nor their feeding habits were altered. A single pharmacokinetic profile was obtained with 5 samples per designated bleeding time, sampling each cat 2–3 times only. None of the cats rejected their medicated food or morsels. Plasma profile of enrofloxacin exhibited an AUC0–24 value of 12.4 µg·h/mL and an AUC0–∞ value of 19.2 µg·h/mL, which are comparatively greater than values previously referred for kittens. In contrast, λ and elimination t½ were almost identical (0.12 1/h and 6.1 h). Pharmacokinetics/pharmacodynamics ratios taking the breakpoint of Staphylococcus epidermidis as a surrogate (0.5 µg/mL), can be regarded as borderline or low, but perhaps adequate in cats, as higher concentrations may be linked to toxicity (AUC0–24/MIC = 24.8; Cmax/MIC = 4.6).

show abstract